<DOC>
	<DOCNO>NCT01803607</DOCNO>
	<brief_summary>The purpose study assess extent sequential treatment odanacatib result incremental gain bone mineral density ( BMD ) time female participant receive least 3 year bisphosphonate therapy .</brief_summary>
	<brief_title>Efficacy Safety Odanacatib Postmenopausal Women Previously Treated With Oral Bisphosphonate ( MK-0822-076 )</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<mesh_term>Calcium Carbonate</mesh_term>
	<criteria>Postmenopausal ≥5 year ( defined menses least 5 year least 5 year post bilateral oophorectomy ) . Prior current treatment oral bisphosphonate therapy ( i.e. , alendronate , risedronate , ibandronate ) postmenopausal osteoporosis ≥3 year . BMD Tscore hip site ( femoral neck , trochanter , total hip ) ≤2.5 &gt; 3.5 assess dualenergy Xray absorptiometry ( DXA ) without history prior fragility fracture . For participant history prior fragility fracture ( except hip fracture ) , BMD Tscore ≤1.5 &gt; 3.5 hip site . Serum 25hydroxyvitamin D level ≥20 ≤60 ng/mL within 90 day time randomization . Evidence metabolic bone disorder osteopenia osteoporosis History current evidence hip fracture . History malignancy ≤5 year prior sign inform consent , except adequately treat basal cell squamous cell skin cancer situ cervical cancer . Active parathyroid disease . Participant document history parathyroid disease consider inclusion normal parathyroid hormone ( PTH ) screening . History thyroid disease adequately controlled medication . Current treatment antiseizure medication , index calcium metabolism within normal limit . Prior treatment strontiumcontaining product ; intravenous bisphosphonates ; cathepsin K inhibitor ; RANK ligand inhibitor ; fluoride treatment dose great 1 mg/day 2 week . Use follow medication within 6 month prior screen visit : activate vitamin D ; estrogen , without progestin , dose high enough systemic effect ; raloxifene selective estrogen receptor modulator ( SERM ) , tibolone aromatase inhibitor ; subcutaneous calcitonin ( Note : use intranasal calcitonin allow time ) ; anabolic steroid ; PTH ( 134 184 ) ; growth hormone ; systemic glucocorticoid ( ≥5 mg/day prednisone equivalent ) 2 week ; cyclosporine 2 week . Concurrent use cancer chemotherapy heparin ; protease inhibitor human immunodeficiency virus ( HIV ) treatment ; vitamin A ( exclude beta carotene ) &gt; 10,000 IU daily , unless willing discontinue dose study . Current treatment cytochrome P450 3A4 ( CYP3A4 ) inducer treatment CYP3A4 inducer within 4 week screen .</criteria>
	<gender>Female</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>